Abstract:HIV-1 (Human immunodeficiency virus-1) has been causing severe pandemics by attacking the immune system of its host. Left untreated, it can lead to AIDS (acquired immunodeficiency syndrome), where death is inevitable due to opportunistic diseases. Therefore, discovering new antiviral drugs against HIV-1 is crucial. This study aimed to explore a novel machine learning approach to classify compounds that inhibit HIV-1 integrase and screen the dataset of repurposing compounds. The present study had two main stages: selecting the best type of fingerprint or molecular descriptor using the Wilcoxon signed-rank test and building a computational model based on machine learning. In the first stage, we calculated 16 different types of fingerprint or molecular descriptors from the dataset and used each of them as input features for 10 machine-learning models, which were evaluated through cross-validation. Then, a meta-analysis was performed with the Wilcoxon signed-rank test to select the optimal fingerprint or molecular descriptor types. In the second stage, we constructed a model based on the optimal fingerprint or molecular descriptor type. This data followed the machine learning procedure, including data preprocessing, outlier handling, normalization, feature selection, model selection, external validation, and model optimization. In the end, an XGBoost model and RDK7 fingerprint were identified to be the most suitable. The model achieved promising results, with an average precision of 0.928 ± 0.027 and an F1-score of 0.848 ± 0.041 in cross-validation. The model achieved an average precision of 0.921 and an F1-score of 0.889 in external validation. Molecular docking was performed and validated by redocking for docking power and retrospective control for screening power, with the AUC metrics being 0.876 and the threshold being identified at –9.71 kcal/mol. Finally, 44 compounds from DrugBank repurposing data were selected from the QSAR model, then three candidates were identified as potential compounds from molecular docking, and PSI-697 was detected as the most promising molecule, with in vitro experiment being not performed (docking score: -17.14 kcal/mol, HIV integrase inhibitory probability: 69.81%)

Dynamic pharmacophore model optimization: identification of novel HIV-1 integrase inhibitors.

Discovery of structurally diverse HIV-1 integrase inhibitors based on a chalcone pharmacophore.

Mining the NCI antiviral compounds for HIV-1 integrase inhibitors.

Identification of a Novel HIV‐1 Integrase Strand Transfer Inhibitor: A Synergistic Approach Combining Pharmacophore Modelling and In Vitro Assays

Design of HIV-1 Integrase Inhibitors Targeting the Catalytic Domain As Well As Its Interaction with LEDGF/p75: A Scaffold Hopping Approach Using Salicylate and Catechol Groups

Screening Novel HIV-1 Protease Inhibitors Based on the Substrate Envelope Hypothesis

Prediction of the Binding Mode between the Small Peptide Inhibitor EBR28 with Integrase through Molecular Modeling Methods

Atom-based 3D-QSAR, molecular docking, DFT, and simulation studies of acylhydrazone, hydrazine, and diazene derivatives as IN-LEDGF/p75 inhibitors

Structure-Guided Antiviral Peptides Identification Targeting the HIV-1 Integrase

Identification of Spirocyclic or Phosphate Substituted Quinolizine Derivatives As Novel HIV-1 Integrase Inhibitors: a Patent Evaluation of WO2016094197A1, WO2016094198A1 and WO2016154527A1

Design and Discovery of Flavonoid-Based HIV-1 Integrase Inhibitors Targeting Both the Active Site and the Interaction with LEDGF/p75

3D-QSAR Modeling, Surflex Docking and Reverse Docking Studies of Diketo-Acid Derivatives as Potent Integrase/Rnase H Inhibitors

Combined molecular docking, molecular dynamics simulation and quantitative structure–activity relationship study of pyrimido[1,2-c][1,3]benzothiazin-6-imine derivatives as potent anti-HIV drugs

Discovery of A Novel 5-Carbonyl-1h-imidazole-4-carboxamide Class of Inhibitors of the Hiv-1 Integrase-Ledgf/P75 Interaction

Discovery of Inhibitors to Block Interactions of HIV-1 Integrase with Human LEDGF/p75 Via Structure-Based Virtual Screening and Bioassays.

Molecular Modeling Study on the Allosteric Inhibition Mechanism of HIV-1 Integrase by LEDGF/p75 Binding Site Inhibitors

Design, Synthesis and Evaluation of Novel HIV-1 NNRTIs with Dual Structural Conformations Targeting the Entrance Channel of the NNRTI Binding Pocket

Rational design and synthesis of novel dimeric diketoacid-containing inhibitors of HIV-1 integrase: implication for binding to two metal ions on the active site of integrase.

Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification

Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.

Novel machine learning approach toward classification model of HIV-1 integrase inhibitors